Target intelligence / Profile preview

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP)

Target
LHPP
Molecular classification
Enzyme, HAD-like hydrolase family, Phosphatase
01

Overview

Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) is a hydrolase enzyme that catalyzes the removal of phosphate groups from phospholysine, phosphohistidine, and inorganic pyrophosphate, acting on both nitrogen-phosphorus and oxygen-phosphorus bonds. LHPP is considered a member of the haloacid dehalogenase (HAD)-like hydrolase family and functions as a homodimer, localized primarily in the cytosol and nuclear specks. It plays a crucial role in maintaining cellular phosphate homeostasis and acts as a tumor suppressor, with reduced expression observed in various cancers. The tumor-suppressive effects of LHPP involve inhibition of key oncogenic signaling pathways, regulation of cell cycle, and promotion of apoptosis. It does not currently have known interacting drugs or approved small-molecule modulators, but LHPP and its pathways are under study for their prognostic and therapeutic relevance, particularly as a biomarker and therapeutic target in oncology.

Other names
LHPPhLHPPHDHD2BPhospholysine phosphohistidine inorganic pyrophosphate phosphatase (full synonym)
02

Mechanism of action

Not established for any approved drugs; as a phosphatase, potential MOA would be via inhibition or modulation of LHPP’s catalytic activity

03

Biological functions

Inorganic diphosphate phosphatase activityProtein phosphatase activity (dephosphorylation of phospholysine, phosphohistidine)Regulation of phosphate-containing compound metabolic processesRegulation of cell proliferation, invasion, migration, and apoptosis (tumor suppressive)Modulation of signaling pathways (PI3K/AKT, TGF-β/Smad, Wnt/β-catenin)
04

Disease associations

Cancer (Hepatocellular carcinoma, gastric cancer, cervical cancer, bladder cancer, colorectal cancer, thyroid carcinoma, pancreatic cancer, oral and laryngeal squamous cell carcinoma, prostate cancer, renal cell carcinoma, intrahepatic cholangiocarcinoma, glioblastoma)Neurological disorders (possible association)
05

Biomarkers

LHPP expression (biomarker of prognosis in several cancers, including gastric, liver, and other solid tumors)Potential biomarker for targeted therapy involving IGF1R inhibition in gastric cancer

Beyond the preview

Go deeper on Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call